Liverpool In-Person Patient Education Day

We are excited to invite you to our upcoming In-Person Patient Education Day in Liverpool this September.
This free education day will include the following topics:

• Navigating Lymphoma and CLL: Your Guide to the Latest Treatments
• Lymphoma and CLL Clinical Trials
• Life after Lymphoma Treatment

Complimentary afternoon tea will be provided.

If you would like to hear this session delivered in Arabic or Vietnamese, please indicate on the registration form.

Guest Speakers

Dr Minh Hua

Dr Minh Hua is a Senior Staff Specialist Haematologist at Liverpool Hospital and Conjoint Senior Lecturer UNSW, who provides consultative services to the Bowral area. She is interested in both malignant and non-malignant Haematology.

Dr Hua completed her Haematology training at Royal Prince Alfred Hospital/Prince of Wales Hospital and has Fellowships from both the Royal Australian College of Physicians and Royal College of Pathologists of Australa special interest in lymphomas, multiple myeloma, myelodysplastic syndromes, acute leukaemia, as well as platelet and coagulation disorders.

Her professional memberships include:
• Royal Australasian College of Physicians (Haematology)
• Royal College of Pathologists Australasia (Haematology)
• Member of Haematology Society of Australia and New Zealand 

Michelle Luong

Michelle Luoung holds a Bachelor of Pharmacy and began her career practicing in a community pharmacy setting before transitioning into clinical trials as an intern. Following the successful completion of her internship, she progressed into the role of Clinical Research Coordinator in haematology.

Michelle has worked across Phase I to Phase III clinical trials involving lymphoma, multiple myeloma, and leukaemia. Her strong attention to detail, dedication to patient care, and compassionate nature are evident in her role as a coordinator.

Today, Michelle feels highly aligned with the work she does every day and is passionate about contributing to the development of future treatment options for patients within the South Western Sydney community. Her work in clinical research plays an important role in advancing innovative therapies and improving health outcomes for future generations.

Nicole Weekes, Lymphoma Care Nurse, Lymphoma Australia

Nicole Weekes is a Lead Lymphoma Care Nurse working across Lymphoma Australia and South Western Sydney Local Health District. She has over 17 years of haematology nursing experience and holds a Master’s degree in Cancer and Haematology Nursing.
 
Nicole is recognised for delivering advanced, patient‑centred care across the full haematology continuum, from diagnosis through to survivorship. She coordinates complex treatments and supports patients to achieve their best possible outcomes.
 
Known for her compassionate approach, Nicole offers kind, consistent emotional support to patients and their families during what is often a highly challenging time, ensuring they feel informed, supported, and empowered throughout their journey.

Agenda

Arrival 2pm Registrations
Presentation 1 2pm
Navigating Lymphoma and CLL: Your Guide to the Latest Treatments – Dr Minh Hua, Staff Specialist Haematologist
Presentation 2 2:45pm
Lymphoma and CLL Clinical Trials –Michelle Luong, Haematology Clinical Research Coordinator
Presentation 3 3:30pm
Life after Lymphoma Treatment –Nicole Weekes, Haematology CNS and Lymphoma Care Nurse
Close 4:00pm Wrap Up and Close

 

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Friday 25th of September 2026
Time: 2:00pm AEST - 4:00pm AEST
Location: Ingham Institute for Applied Medical Research
1 Campbell St, Liverpool NSW

Support and information

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.